Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16575396 | 0.82 | KDM4E (0.32) | KDM4EALDH1A1GAAHPGDPOLB | |
| SCHEMBL6657408 | 0.72 | KDM4E (0.38) | KDM4EALDH1A1GAAHPGDPOLB | |
| SCHEMBL16575417 | 0.70 | HRH4 (0.30) | — | |
| SCHEMBL23137446 | 0.67 | GLA (0.31) | — | |
| SCHEMBL290449 | 0.67 | GCGR (0.45) | GCGRKDM4EALDH1A1HPGDPOLB | |
| SCHEMBL6656229 | 0.66 | GCGR (0.32) | GCGR | |
| SCHEMBL13616982 | 0.65 | — | — | |
| SCHEMBL16924567 | 0.65 | LMNA (0.34) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL17411546 | 0.65 | SMN1; SMN2 (0.31) | GCGRKDM4EALDH1A1GAAHPGD | |
| SCHEMBL6162687 | 0.65 | MAPK1 (0.38) | KDM4EALDH1A1GAAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | GCGR 1757/4885KDM4E 3359/4885ALDH1A1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.